Amcasertib (BBI503) is primarily investigated for its potential in cancer treatment, particularly in targeting cancer stem cells. It works by inhibiting key signaling pathways that are crucial for the survival and proliferation of these cells, which are often resistant to conventional therapies. This makes it a promising candidate for treating various types of cancers, including those that are difficult to manage with existing treatments. Clinical trials are ongoing to evaluate its efficacy and safety in patients, with a focus on its ability to reduce tumor growth and prevent recurrence. Its application could potentially improve outcomes in cancers with high rates of relapse and metastasis.